

# Tidal Volume Lower than 6 ml/kg Enhances Lung Protection

## Role of Extracorporeal Carbon Dioxide Removal

Pier Paolo Terragni, M.D.,\* Lorenzo Del Sorbo, M.D.,\* Luclana Mascla, M.D., Ph.D.,\* Rosario Urbino, M.D.,\* Erica L. Martin, Ph.D.,\* Alberto Birocco, M.D.,† Chiara Faggiano, M.D.,† Michael Quintel, M.D.,‡ Luciano Gattinoni, M.D.,§ V. Marco Ranieri, M.D.||

**Background:** Tidal hyperinflation may occur in patients with acute respiratory distress syndrome who are ventilated with a tidal volume ( $V_T$ ) of 6 ml/kg of predicted body weight develop a plateau pressure ( $P_{PLAT}$ ) of  $28 \leq P_{PLAT} \leq 30$  cm H<sub>2</sub>O. The authors verified whether  $V_T$  lower than 6 ml/kg may enhance lung protection and that consequent respiratory acidosis may be managed by extracorporeal carbon dioxide removal.

**Methods:**  $P_{PLAT}$ , lung morphology computed tomography, and pulmonary inflammatory cytokines (bronchoalveolar lavage) were assessed in 32 patients ventilated with a  $V_T$  of 6 ml/kg. Data are provided as mean  $\pm$  SD or median and interquartile (25th and 75th percentile) range. In patients with  $28 \leq P_{PLAT} \leq 30$  cm H<sub>2</sub>O ( $n = 10$ ),  $V_T$  was reduced from  $6.3 \pm 0.2$  to  $4.2 \pm 0.3$  ml/kg, and  $P_{PLAT}$  decreased from  $29.1 \pm 1.2$  to  $25.0 \pm 1.2$  cm H<sub>2</sub>O ( $P < 0.001$ ); consequent respiratory acidosis ( $Paco_2$  from  $48.4 \pm 8.7$  to  $73.6 \pm 11.1$  mmHg and pH from  $7.36 \pm 0.03$  to  $7.20 \pm 0.02$ ;  $P < 0.001$ ) was managed by extracorporeal carbon dioxide removal. Lung function, morphology, and pulmonary inflammatory cytokines were also assessed after 72 h.

**Results:** Extracorporeal assist normalized  $Paco_2$  ( $50.4 \pm 8.2$  mmHg) and pH ( $7.32 \pm 0.03$ ) and allowed use of  $V_T$  lower than 6 ml/kg for 144 (84–168) h. The improvement of morphological markers of lung protection and the reduction of pulmonary

cytokines concentration ( $P < 0.01$ ) were observed after 72 h of ventilation with  $V_T$  lower than 6 ml/kg. No patient-related complications were observed.

**Conclusions:**  $V_T$  lower than 6 ml/kg enhanced lung protection. Respiratory acidosis consequent to low  $V_T$  ventilation was safely and efficiently managed by extracorporeal carbon dioxide removal.

LIMITATION of tidal volume ( $V_T$ ) to 6 ml/kg predicted body weight (PBW) and of end-inspiratory plateau pressure ( $P_{PLAT}$ ) to a maximum of 30 cm H<sub>2</sub>O represents the standard for mechanical ventilation of patients with acute respiratory distress syndrome (ARDS).<sup>1,2</sup> However, recent studies found that (1) tidal hyperinflation may occur in some patients despite limiting  $V_T$  to 6 ml/kg and  $P_{PLAT}$  to 30 cm H<sub>2</sub>O,<sup>3</sup> (2) ARDS patients may benefit from  $V_T$  reduction even if they already have  $P_{PLAT} < 30$  cm H<sub>2</sub>O.<sup>4</sup>

Extracorporeal assist separating carbon dioxide removal from oxygen uptake has been proposed by Gattinoni *et al.*<sup>5</sup> With this technique, carbon dioxide is removed by a pump-driven veno-venous bypass, and oxygenation is accomplished by high levels of positive end-expiratory pressure (PEEP) and three to five sighs every minute.<sup>5</sup> Although effective,<sup>5</sup> negative results of a clinical trial,<sup>6</sup> the extensive amount of required resources,<sup>7</sup> and the high incidence of side effects<sup>8</sup> restricted the use of extracorporeal carbon dioxide removal as "rescue" therapy for the most severe case of ARDS.<sup>9</sup>

To reduce complexity, expenses, and side effects of extracorporeal lung assistance, Pesenti *et al.* proposed the concept of removing "only a portion of carbon dioxide production" to allow less traumatic ventilator settings.<sup>10</sup> The current study set up to examine the hypothesis that a modified renal replacement circuit incorporating a neonatal membrane lung coupled in series with a hemofilter may safely remove the amount of carbon dioxide sufficient to buffer the respiratory acidosis associated to  $V_T$  lower than 6 ml/kg and allow more protective ventilatory settings.

## Materials and Methods

### Patient Selection

Patients admitted from July 2006 to September 2007 in the intensive care units of the S. Giovanni Battista-Molinette hospital (University of Turin, Turin, Italy) were enrolled. Inclusion criteria were age of at least 18 yr and diagnosis

This article is accompanied by an Editorial View. Please see: Bigatello LM, Pesenti A: Ventilator-induced lung injury: less ventilation, less injury. ANESTHESIOLOGY 2009; 111:699-700.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are available in both the HTML and PDF versions of this article. Links to the digital files are provided in the HTML text of this article on the Journal's Web site ([www.anesthesiology.org](http://www.anesthesiology.org)).

\* Assistant Professor of Medicine, † Resident in Anesthesia, || Professor of Anesthesia, Dipartimento di Anestesiologia e Medicina degli Stati Critici, Università di Torino, Ospedale S. Giovanni Battista-Molinette, Torino, Italy; ‡ Professor of Anesthesia, Department of Anesthesiology, University of Göttingen, Göttingen, Germany; § Professor of Anesthesia, Istituto di Anestesia e Rianimazione, Fondazione IRCCS - Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena di Milano, and Università degli Studi di Milano, Italy.

Received from Dipartimento di Anestesiologia e Medicina degli Stati Critici, Università di Torino, Ospedale S. Giovanni Battista-Molinette, Torino, Italy. Submitted for publication March 2, 2009. Accepted for publication June 2, 2009. Supported by grant PR60ANRA07 from Ministero Università e Ricerca (Rome, Italy) and by grant Z2BT-06 from Regione Piemonte (Turin, Italy). Drs. Ranieri and Quintel are members of the advisory board of Hemosol, Salerno, Italy (Dr. Roberto Intennimeo: [r.intennimeo@hemosol.com](mailto:r.intennimeo@hemosol.com)) and for this will receive €29,000 annually (2008-2010).

Address correspondence to Dr. Ranieri: Università di Torino, Dipartimento di Anestesiologia e di Medicina degli Stati Critici, Ospedale S. Giovanni Battista-Molinette, Corso Dogliotti 34, 10126 Torino, [mario.ranieri@unito.it](mailto:mario.ranieri@unito.it). This article may be accessed for personal use at no charge through the Journal Web site, [www.anesthesiology.org](http://www.anesthesiology.org).

of ARDS.<sup>11</sup> Exclusion criteria were more than 3 days since they met ARDS criteria, pulmonary artery occlusion pressure greater than 18 mmHg, history of ventricular fibrillation, tachyarrhythmia, unstable angina, or myocardial infarction within preceding month, chronic obstructive pulmonary disease, chest wall abnormalities, chest tube, abdominal distension, body mass index greater than 30, pregnancy, intracranial abnormality.<sup>12</sup>

The institutional review board (Comitato Etico Inverziendale, Regione Piemonte, Turin) approved the study. If the patient was incompetent at study entry, consent was delayed, the family was informed of the study (although not required), and the study was performed. Written permission for using collected data were hence obtained from the patient (if competent) or from the family (in case of death or if the patient remained incompetent).<sup>13</sup>

#### Study Protocol

All consecutive patients who met inclusion and exclusion criteria were treated for 72 h according to the ARDSNet strategy.<sup>2</sup> A detailed description of the protocol can be found in the Supplemental Digital Content (see text file, Supplemental Digital Content 1, <http://links.lww.com/ALN/A542>).

After 72 h of ventilation according to the ARDSNet strategy,<sup>2</sup>  $P_{PLAT}$  was recorded for a period of 1 h with 0.5-s inspiratory pause keeping ventilator setting constant and abolishing spontaneous respiratory muscles activity by (1) reaching a Ramsay score of sedation 5 (midazolam up to  $0.15 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ , morphine up to  $0.03 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ , and propofol up to  $2 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ ); (1) increasing, if required before measurements, doses of midazolam (up to 10 mg/h) and/or propofol (150 mg/h increments every 10 min).<sup>15,16</sup>

In the patients who had  $25 < P_{PLAT} < 28 \text{ cm H}_2\text{O}$ , the ARDSNet strategy<sup>2</sup> was maintained at least for the subsequent 72 h (fig. 1). In patients who had  $28 \leq P_{PLAT} \leq 30 \text{ cm H}_2\text{O}$ , the following strategy was implemented and maintained for at least the next 72 h (fig. 1): (1)  $V_T$  was stepwise reduced (1 ml/kg of PBW every 4 h) until  $25 < P_{PLAT} < 28 \text{ cm H}_2\text{O}$ ; (2) to manage the reabsorption atelectasis that may occur during mechanical ventilation with low  $V_T$ ,<sup>17,18</sup> PEEP-FiO<sub>2</sub> combination was set according to the "higher PEEP" arm of the ALVEOLI study<sup>12</sup>; (3) respiratory rate was increased up to 40 breaths/min, and bicarbonate was infused up to 20 mEq/h; (4) if pH was no more than 7.25, extracorporeal carbon dioxide removal was initiated by using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 0.33 m<sup>2</sup> (Decap<sup>®</sup>, Hemodec, Salerno, Italy)<sup>19</sup> (Lower ARDSNet/Carbon Dioxide Removal; fig. 2).

Femoral vein was accessed *via* a double lumen catheter (14 F; Arrow International Inc. Reading, PA) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow was driven through the circuit by a roller nonocclusive low-flow pump (0-




Fig. 1. Study design. ARDS = acute respiratory distress syndrome; ARDS network strategy = ARDSNet strategy; BAL = bronchoalveolar lavage; CT = computed tomography;  $F_{iO_2}$  = inspired O<sub>2</sub> fraction; PEEP = positive end-expiratory pressure;  $P_{PLAT}$  = end-inspiratory plateau pressure;  $V_T$  = tidal volume. All patients in the Lower ARDSNet/Carbon Dioxide Removal arm met pH criteria for carbon dioxide removal and were therefore connected to the veno-venous bypass.

500 ml/min) through a membrane lung (Polystan SAFE; Maquet, Rastatt, Germany) that was connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 l/min. Exiting the membrane lung, blood was driven to a hemofilter (Medica D200, Medolla, Italy). The resulting plasmatic water was recirculated through the membrane lung by a peristaltic pump (0-155 ml/min).

The membrane lung and the hemofilter were coupled in series to: (1) increase the pressure inside the membrane lung by adding the downstream resistance exerted by the hemofilter and therefore reduce the risk of air bubble formation<sup>20</sup>; (2) minimize the need for heparin by diluting the blood entering the membrane lung by recirculating the plasmatic water separated by the hemofilter<sup>21</sup>; (3) enhance the performance of the extracorporeal device extracting the carbon dioxide dissolved in the plasmatic water separated by the hemofilter and recirculated through the membrane lung<sup>22</sup> (fig. 2).

Pressure developed by the roller pump (arterial pressure) was measured and limited to 120-150 mmHg. Reinfusion pressure (venous pressure) and the pressure gradient across the membrane lung and the hemofilter (drop pressure = premembrane lung pressure - venous pressure) were also measured. Detectors of leaks and bubbles were inserted within the circuit. The circuit, including the membrane lung was primed with saline with a volume that ranged between 140 and 160 ml.

A starting dose of heparin (80 IU/kg bolus and 18 IU · kg<sup>-1</sup> · h<sup>-1</sup> infusion) was delivered by using a syringe




Fig. 2. Extracorporeal carbon dioxide removal device used in the study. The system consisted of a standard continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 0.33 m<sup>2</sup>.

pump included in the system. Heparin continuous infusion was hence titrated to maintain the activated partial thromboplastin time ratio to approximately 1.5.

After 72 h of Lower ARDSNet/Carbon Dioxide Removal strategy, the following weaning trial was conducted once a day: flow through the circuit was set to the lowest value (50 ml/min),  $V_T$  was increased to 6 ml/kg PBW, and PEEP- $F_{IO_2}$  combination was set according to the conventional ARDSNet strategy.<sup>2</sup> If  $P_{PLAT}$  with these ventilator settings remained for more than 3 h at less than 28 cm H<sub>2</sub>O, extracorporeal carbon dioxide removal was interrupted, and conventional ARDSNet ventilatory strategy reestablished.

#### Measurements

Underlying disease responsible for ARDS, clinical status, and laboratory data on admission (the worst value within 24 h after admission) were recorded for calculation of the Simplified Acute Physiology Score II.<sup>23</sup>

#### Clinical Variables

Clinical variables ( $P_{PLAT}$ ,  $V_T$ , respiratory rate, PEEP, minute ventilation,  $P_{AO_2}/F_{IO_2}$  ratio,  $P_{aCO_2}$ , pH, continuous cardiac output [Vigileo system; Edwards LifeScience, Irvine, CA], heparin doses, and activated partial thromboplastin time ratio) were prospectively collected at the following scheduled times: after 72 h of ventilation according to the conventional ARDSNet strategy and, in

those patients who had  $28 \leq P_{PLAT} \leq 30$  cm H<sub>2</sub>O, after lowering  $V_T$  and before initiating carbon dioxide removal (baseline) and after 60–90 min ( $T_{1.5}$ ), 24 h ( $T_{24}$ ), 48 h ( $T_{48}$ ), and 72 h ( $T_{72}$ ) after initiation of carbon dioxide removal. Blood flow during carbon dioxide removal was recorded at  $T_{1.5}$ ,  $T_{24}$ ,  $T_{48}$ , and  $T_{72}$ .

Potential complications during the procedure were prospectively classified as mechanical (cannula problems, membrane lung failure, clots in the circuit, air in the circuit, pump malfunction, tubing rupture, catheter displacement, system leaks) and patient-related (vein perforation, significant bleeding [*i.e.*, any bleeding event that required the administration of 1 unit of packed red cells], hemodynamic instability [*i.e.*, 80–90 mmHg increase or a 30–40 mmHg decrease in systolic blood pressure relative to the baseline value or need for inotropic drugs for at least 2 h to maintain systolic blood pressure higher than 85 mmHg or electrocardiogram evidence of ischemia or significant ventricular arrhythmias] ischemic/gangrenous bowel, pneumothorax, renal complications [*i.e.*, occurrence after initiation of carbon dioxide removal of creatinine greater than 1.5 mg/dl], infectious complications [*i.e.*, occurrence after initiation of carbon dioxide removal of culture proven new infection], metabolic [*i.e.*, occurrence after initiation of carbon dioxide removal of glucose of at least 240 mg/dl or hyperbilirubinemia], thromboembolic complications [*i.e.*, occurrence after initiation of deep venous thrombosis or

pulmonary embolus], and neurologic complications [*i.e.*, occurrence after initiation of carbon dioxide removal of cerebral infarction, or clinical seizure, or cerebral hemorrhage or cerebral edema]), and their occurrence was recorded during the period that the Lower ARDSNet/Carbon Dioxide Removal strategy was recorded.

#### Lung Morphology

A pulmonary computed tomography (CT) scan of the whole lung was performed in all patients after study enrollment. The CT scan was repeated after approximately 72 h of ventilation with the Lower ARDSNet/Carbon Dioxide Removal strategy in those patients who had  $28 \leq P_{\text{PLAT}} \leq 30$  cm H<sub>2</sub>O and after approximately 72 h of ventilation with the conventional ARDSNet strategy in some of the patients who had  $25 < P_{\text{PLAT}} < 28$  cm H<sub>2</sub>O (fig. 1). (See text file, Supplemental Digital Content 1, which is a detailed description of the methods used, <http://links.lww.com/ALN/A542>).<sup>5</sup>

Weight and volume of the entire lungs and of the nonaerated, poorly aerated, normally aerated, and hyperinflated compartments were assessed.<sup>13,24</sup> Protected tidal inflation and tidal hyperinflation were defined as the volume of the normally aerated and hyperinflated compartment at end-inspiration minus the volume of the normally aerated and hyperinflated compartment at end-expiration, respectively. Tidal recruitment of the nonaerated compartment was defined as the volume of the nonaerated compartment at end-expiration minus the volume at end-inspiration. All were expressed as percent of the total tidal inflation-related change in CT lung volume.<sup>3,24</sup>

#### Pulmonary Inflammatory Response

A bronchoalveolar lavage was performed in all patients after study enrollment.<sup>25</sup> The bronchoalveolar lavage

was repeated after approximately 72 h of ventilation with the Lower ARDSNet/Carbon Dioxide Removal strategy in the patients who had  $28 \leq P_{\text{PLAT}} \leq 30$  cm H<sub>2</sub>O and after approximately further 72 h of ventilation with the conventional ARDSNet strategy in some of the patients who had  $25 < P_{\text{PLAT}} < 28$  cm H<sub>2</sub>O (fig. 1). Interleukin 6 (IL-6), IL-8, IL-1b, and IL-1 receptor antagonist (IL-1Ra) were measured. (See text file, Supplemental Digital Content 1, which is a detailed description of the methods used, <http://links.lww.com/ALN/A542>).<sup>25</sup>

#### Statistical Analysis

Data are expressed as mean  $\pm$  SD of the mean or median and interquartile (25th and 75th percentile) range as appropriate. To evaluate differences between the two groups, the Fisher exact test for categorical variables and the *t* test with unequal variance for continuous variables were used. Data at different times during carbon dioxide removal were compared by analysis of variance (ANOVA) for repeated measures by using a Bonferroni correction. If significant ( $P \leq 0.05$ ), the values at baseline, T<sub>1.5</sub>, T<sub>24</sub>, T<sub>48</sub>, and T<sub>72</sub> were compared with those obtained after 72 h of ventilation according to the ARDSNet strategy by using a paired *t* test as modified by Dunnett. All tests were two tailed. Analysis was carried out by using the SPSS software package (SPSS Inc. Chicago, IL).

## Results

Of the 32 patients who matched study criteria, 22 patients had  $25 < P_{\text{PLAT}} < 28$  cm H<sub>2</sub>O and 10 patients had  $28 \leq P_{\text{PLAT}} \leq 30$  cm H<sub>2</sub>O. Patient characteristics are shown in table 1. Age, gender, Simplified Acute Physiology Score II, and underlying diseases responsible for ARDS did not

Table 1. Characteristics of the Study Population

	Overall Population (n = 32)	ARDSNet 25 < P <sub>PLAT</sub> < 28 (n = 22)	ARDSNet 28 ≤ P <sub>PLAT</sub> ≤ 30 (n = 10)	P Value
<b>Demographics</b>				
Age, yrs	65.8 ± 12.2	65.2 ± 13.2	64.1 ± 13.5	NS
Male/female	22/10	15/7	7/3	NS
SAPS II	48 ± 20	43 ± 17	56 ± 23	NS
<b>Respiratory variables</b>				
Tidal volume (ml/kg predicted body weight)	6.3 ± 0.7	6.3 ± 0.3	6.3 ± 0.2	NS
Plateau pressure (cm H <sub>2</sub> O)	27.6 ± 1.8	25.2 ± 0.5	29.1 ± 1.2	0.01
PEEP (cm H <sub>2</sub> O)	11.4 ± 2.8	10.3 ± 2.3	12.1 ± 2.3	0.01
Pao <sub>2</sub> /Fio <sub>2</sub> , mmHg	147 ± 56	185 ± 60	136 ± 30	0.003
Minute ventilation (l/min)	10.4 ± 2.6	9.5 ± 2.8	11.5 ± 1.6	0.01
Paco <sub>2</sub> , mmHg	48.9 ± 7.1	43.5 ± 6.4	48.4 ± 8.7	NS
Arterial pH	7.37 ± 0.02	7.38 ± 0.01	7.36 ± 0.03	NS
<b>Causes of lung injury</b>				
Pneumonia, n (%)	11 (34)	8 (36)	4 (40)	NS
Sepsis, n (%)	16 (50)	10 (45)	5 (50)	NS
Trauma, n (%)	5 (16)	4 (18)	1 (10)	NS

Data are mean  $\pm$  SD.

Fio<sub>2</sub> = inspiratory O<sub>2</sub> fraction; Paco<sub>2</sub> = arterial CO<sub>2</sub> partial pressure; Pao<sub>2</sub> = arterial O<sub>2</sub> partial pressure; PEEP = positive end-expiratory pressure; SAPS = simplified acute physiological score.

Table 2. Quantitative CT Scan of the Study Population

	Overall Population (n = 32)	ARDSNet 25 < P <sub>PLAT</sub> < 28		ARDSNet 28 ≤ P <sub>PLAT</sub> ≤ 30	
		Study Entry (n = 22)	After 72 h of Conventional ARDSNet (n = 12)	Study Entry (n = 10)	After 72 h of Lower ARDSNet/Carbon Dioxide Removal (n = 10)
Lung weight, g	1,681 ± 466	1,488 ± 513	1,143 ± 234§	1,919 ± 402*	1,519 ± 106#
End Inspiratory CT lung compartments, % total lung volume					
Non-aerated (+100 and -100 HU)	16.2 ± 7.8	12.6 ± 8.7	3.1 ± 1.1§	23.2 ± 7.0*	12.3 ± 2.6#
Poorly aerated (-101 and -500 HU)	14.3 ± 6.1	11.2 ± 6.5	1.1 ± 0.3§	16.3 ± 2.8*	11.4 ± 6.7#
Normally aerated (-501 and -900 HU)	58.7 ± 10.5	72.3 ± 10.1	94.5 ± 3.8§	40.1 ± 9.5*	75.5 ± 8.8#
Hyperinflated (-901 and -1,000 HU)	10.6 ± 8.5	3.9 ± 3.4	1.3 ± 0.2§	20.4 ± 4.4*	0.8 ± 0.7#

Data are mean ± SD.

\* P < 0.001 ARDSNet 25 < P<sub>PLAT</sub> < 28 cm H<sub>2</sub>O at study entry vs. ARDSNet 28 ≤ P<sub>PLAT</sub> ≤ 30 cm H<sub>2</sub>O at study entry; § P < 0.05 ARDSNet 25 < P<sub>PLAT</sub> < 28 cm H<sub>2</sub>O, study entry vs. after 72 h of conventional ARDSNet; # P < 0.001 ARDSNet 28 ≤ P<sub>PLAT</sub> ≤ 30 cm H<sub>2</sub>O, study entry vs. 72 h of Lower ARDSNet/Carbon Dioxide Removal.

CT = computed tomography.

differ between the two groups. P<sub>a</sub>CO<sub>2</sub>:F<sub>i</sub>O<sub>2</sub> ratio was lower in patients with 28 ≤ P<sub>PLAT</sub> ≤ 30 cm H<sub>2</sub>O than in patients with 25 < P<sub>PLAT</sub> < 28 cm H<sub>2</sub>O (P < 0.01).

Lungs were heavier, and the extent of the hyperinflated, nonaerated, and poorly aerated CT lung compartments was larger and the extent of the normally aerated compartment was smaller in patients with 28 ≤ P<sub>PLAT</sub> ≤ 30 cm H<sub>2</sub>O than in patients with 25 < P<sub>PLAT</sub> < 28 cm H<sub>2</sub>O (all P < 0.001) (table 2). Protected tidal inflation was smaller and tidal hyperinflation was larger in patients who had 28 ≤ P<sub>PLAT</sub> ≤ 30 cm H<sub>2</sub>O than in the patients who had 25 < P<sub>PLAT</sub> < 28 cm H<sub>2</sub>O (19 ± 6 vs.

81 ± 6 and 67 ± 5 vs. 11 ± 4% of the total tidal inflation-associated change in CT lung compartments, respectively; P < 0.01). Tidal recruitment of the poorly aerated compartment did not differ between the two groups of patients.

In the patients who had 28 ≤ P<sub>PLAT</sub> ≤ 30 cm H<sub>2</sub>O, V<sub>T</sub> was decreased from 6.3 ± 0.2 to 4.2 ± 0.3 ml/kg PBW and P<sub>PLAT</sub> decreased from 29.1 ± 1.2 to 25.0 ± 1.2 cm H<sub>2</sub>O (all P < 0.001). Despite the increase in respiratory rate (from 31.2 ± 2.3 to 37.0 ± 1.9 breaths/min; P < 0.001) and bicarbonate infusion (20.2 ± 0.8 mEq/h), the reduction in minute ventilation (from 12.03 ± 2.77 to





Fig. 3. Individual and average (horizontal bar) values of tidal volume (V<sub>T</sub>), plateau pressure (P<sub>PLAT</sub>), positive end expiratory pressure (PEEP), and arterial to inspired O<sub>2</sub> fraction ratio (P<sub>a</sub>O<sub>2</sub>/F<sub>i</sub>O<sub>2</sub>) during acute respiratory distress syndrome network ("ARDSNet") strategy after lowering V<sub>T</sub> and before initiating carbon dioxide removal (baseline), and 60–90 min (T<sub>1.5</sub>), 24 h (T<sub>24</sub>), 48 h (T<sub>48</sub>), and 72 (T<sub>72</sub>) after initiation of carbon dioxide removal. \* P < 0.01 versus ARDSNet strategy.

Fig. 4. Individual and average (horizontal bar) values of arterial carbon dioxide partial pressure ( $\text{PaCO}_2$ ) and arterial pH during acute respiratory distress syndrome network (ARDSNet) strategy after lowering tidal volume and before initiating carbon dioxide removal (baseline), and 60–90 min ( $T_{1.5}$ ), 24 h ( $T_{24}$ ), 48 h ( $T_{48}$ ), and 72 h ( $T_{72}$ ) after initiation of carbon dioxide removal. \*  $P < 0.001$  versus ARDSNet ventilation.



$9.03 \pm 1.18$  l/min;  $P < 0.001$ ) increased  $\text{PaCO}_2$  (from  $48.4 \pm 8.7$  to  $73.6 \pm 11.1$  mmHg;  $P < 0.001$ ) and decreased pH (from  $7.36 \pm 0.03$  to  $7.20 \pm 0.02$ ;  $P < 0.001$ ). The increase in PEEP (from  $12.1 \pm 2.5$  cm  $\text{H}_2\text{O}$  to  $15.2 \pm 0.8$  cm  $\text{H}_2\text{O}$ ,  $P < 0.001$ ) attenuated the reduction in  $\text{PaO}_2/\text{FiO}_2$  (from  $135 \pm 30$  to  $124 \pm 29$ ;  $P < 0.01$ ) associated to the lowering of  $V_T$  (fig. 3). All patients met pH criteria for carbon dioxide removal and were therefore connected to the veno-venous bypass.

Sixty to ninety minutes of veno-venous bypass decreased  $\text{PaCO}_2$  to  $50.4 \pm 8.2$  mmHg and increased arterial pH to  $7.32 \pm 0.03$  ( $P < 0.001$ ). After 72 h of extracorporeal support,  $\text{PaCO}_2$  and arterial pH were  $47.2 \pm 8.6$  mmHg and  $7.38 \pm 0.04$ , respectively ( $P < 0.001$ ; fig. 4). The extracorporeal veno-venous carbon dioxide removal device was used for 144 (84, 168) h. The pump-driven blood flow through the circuit ranged between 191 and 422 ml/min (5–10% of cardiac output; table 3). Heparin infusion ranging between 3 and 19 IU/kg was needed to maintain activated partial thromboplastin time ratio between 1.1 and 1.7 (table 3).

No patient-related complications were observed. Mechanical complications are reported in table 4. In three cases, the 14-French double-lumen catheter had to be replaced by two 8-French simple-lumen catheters (one for each femoral vein) due to recirculation issues (two cases) and catheter kinking (one case). None of the reported malfunctions impaired patient status during the procedure. The membrane clotting observed in three

patients did not result in additional transfusion. The Lower ARDSNet/Carbon Dioxide Removal strategy did not require any increase in nursing resources. A technician with expertise in the Decap<sup>®</sup> system was present (9 AM–5 PM) during the treatment of the first five patients.

Average lung density histograms of tidal changes in CT lung compartments in patients who had  $28 \leq P_{\text{PLAT}} \leq 30$  cm  $\text{H}_2\text{O}$  during the ARDSNet strategy are shown at study entry (fig. 5A, left) and after 72 h of Lower ARDSNet/Carbon Dioxide Removal strategy (fig. 5A, right). Ventilation with the Lower ARDSNet/Carbon Dioxide Removal was associated with: (1) the reduction of lung weight and of the extent of hyperinflated, nonaerated, and poorly aerated CT lung compartments and an increase of the extent of normally aerated lung compartments ( $P < 0.001$ ; table 2); (2) increase of protected tidal inflation (from  $19 \pm 6\%$  to  $86 \pm 8\%$  of the total tidal inflation-associated change in CT lung compartments;  $P < 0.01$ ); (3) the reduction of tidal hyperinflation (from  $67 \pm 5\%$  to  $5 \pm 4\%$  of the total tidal inflation-associated change in CT lung compartments;  $P < 0.01$ ); (4) a significant improvement of  $\text{PaO}_2/\text{FiO}_2$  (from  $136 \pm 30$  to  $221 \pm 56$ ;  $P < 0.001$ ) (fig. 3). Same data for the patients who during the ARDSNet strategy had  $25 < P_{\text{PLAT}} < 28$  cm  $\text{H}_2\text{O}$  are shown at study entry (fig. 5B, left). In 12 of the 22 patients, CT scans were obtained after further 72 h of conventional ARDSNet strategy (fig. 5B, right); these data were retrospectively obtained by using CT scan performed for other studies or for clinical reasons. Relative to

Table 3. Coagulation Parameters and Blood Flow

	$T_{1.5}$	$T_{24}$	$T_{48}$	$T_{72}$
aPTT ratio*	$1.3 \pm 0.2$	$1.4 \pm 0.1$	$1.5 \pm 0.2$	$1.4 \pm 0.2$
Heparin, IU/kg*	$8 \pm 5$	$11 \pm 7$	$11 \pm 8$	$11 \pm 7$
Blood flow through $\text{CO}_2$ removal device, ml/min*	$348 \pm 74$	$357 \pm 75$	$329 \pm 78$	$282 \pm 91$
Cardiac output, ml/min*	$5.8 \pm 1.3$	$5.6 \pm 1.2$	$5.7 \pm 1.1$	$6.4 \pm 2.3$
Fluid balance, ml†	$530 (-420, 1,545)$	$-215 (-2,944, 2,041)$	$648 (-220, 1,100)$	$119 (-1,062, 625)$

Data are \* mean  $\pm$  standard deviation or † median and Interquartile (25th and 75th percentile) range.

aPTT = activated partial thromboplastin time ratio;  $\text{CO}_2$  = carbon dioxide; IU = International units.

Table 4. Total Number of Mechanical Complications Occurring during the 144 (84, 168)\* Hours of Treatment

	Frequency (n)
Pump malfunction	1
Membrane lung/hemofilter clotting	3
Catheter displacement	1
Cannula problems, i.e. need for two cannulas instead of a single double-lumen	3

\* Median and interquartile (25th and 75th percentile).

study entry, further 72 h of conventional *ARDSNet* strategy were also associated to the reduction of lung weight and of the extent of the hyperinflated, nonaerated, and poorly aerated CT lung compartments and the increase of the extent of the normally aerated lung compartments ( $P < 0.05$ ; table 2) with no changes in amount of protected tidal inflation and tidal hyperinflation (fig. 5B, left); a significant improvement of  $P_{aO_2}/F_{iO_2}$  (from  $185 \pm 60$  to  $301 \pm 42$ ;  $P < 0.001$ ) was also observed.


Pulmonary concentration of inflammatory cytokines at study entry were lower ( $P = 0.001$ ) in patients who during the *ARDSNet* strategy had  $25 < P_{PLAT} < 28$  cm

$H_2O$  than in patients who had  $28 \leq P_{PLAT} \leq 30$  cm  $H_2O$ . In the former, further 72 h of conventional *ARDSNet* strategy did not modify concentration of pulmonary inflammatory cytokines (data were retrospectively obtained in 15 of the 22 patients by using bronchoalveolar lavage performed for other studies). In the latter, the use of the Lower *ARDSNet*/Carbon Dioxide Removal strategy was associated with a significantly reduced concentration of pulmonary inflammatory cytokines ( $P = 0.001$ ; fig. 6). Bronchoalveolar lavage procedure did not cause complications in any of the studied patients.

## Discussion

Use of  $V_T$  lower than 6 ml/kg PBW in patients who during *ARDSNet* ventilation had  $28 \leq P_{PLAT} \leq 30$  cm  $H_2O$  was associated to a significant reduction of inflammatory and morphological markers of ventilator-induced lung injury. Respiratory acidosis consequent to further  $V_T$  reduction was effectively and safely corrected by using a modified renal replacement device incorporating a membrane lung.

### A "ARDSNet" strategy: $28 \leq P_{PLAT} \leq 30$



### B "ARDSNet" strategy: $25 < P_{PLAT} < 28$




Fig. 5. Average lung density histograms of tidal changes in computed tomography of lung compartments in patients who during the acute respiratory distress syndrome network (*ARDSNet*) strategy had  $28 \leq P_{PLAT} \leq 30$  cm  $H_2O$  are shown at study entry (A, left) and after 72 h of Lower *ARDSNet*/Carbon Dioxide Removal strategy (A, right). Same data for the patients who during the *ARDSNet* strategy had  $25 < P_{PLAT} < 28$  cm  $H_2O$  are shown at study entry (B, left) and after further 72 h of conventional *ARDSNet* strategy (B, right).

"ARDSNet" strategy:  $25 < P_{PLAT} < 28$

◇ Entry ( $N = 22$ )


◆ after 72 hrs ( $N = 15$ )

"ARDSNet" strategy:  $28 \leq P_{PLAT} \leq 30$

○ Entry ( $N = 10$ )

● after 72 hrs of LOWER "ARDSNet"/CARBON DIOXIDE REMOVAL ( $N = 10$ )

Fig. 6. Individual and average (horizontal bar) values of pulmonary concentration of inflammatory mediators in patients who at study entry had  $25 < P_{PLAT} < 28$  cm H<sub>2</sub>O and  $28 \leq P_{PLAT} \leq 30$  cm H<sub>2</sub>O during acute respiratory distress syndrome network (ARDSNet) strategy. Values of inflammatory cytokines in the former, after further 72 h of ARDSNet strategy, and in the latter after 72 h of Lower ARDSNet/Carbon Dioxide Removal strategy are also presented. IL-1b = interleukin 1b; IL-1Ra = IL-1 receptor antagonist; IL-6 = interleukin 6; IL-8 = interleukin 8.



These results support the use of extracorporeal carbon dioxide removal as a tool that, integrated with conventional ventilation, allows more protective ventilator settings.<sup>9</sup> However, these data can only be used as proof of principle for the following reasons. (1) The confounding effect of time on the observed improvement of physiologic, radiographic, and inflammatory parameters before and after 72 h of Lower ARDSNet/Carbon Dioxide Removal strategy cannot be ruled out because we don't have a control group of patients with  $28 \leq P_{PLAT} \leq 30$  cm H<sub>2</sub>O who received usual care without Lower ARDSNet/Carbon Dioxide Removal. Moreover, the study design prevents us from knowing what the respective effect of decreasing V<sub>T</sub>, increasing PEEP, and application of carbon dioxide removal. (2) We could not assess whether the observed substantial decrease in Paco<sub>2</sub> with the limited blood flow was exclusively related to the device used in the study; measurements of extracorporeal carbon dioxide transfer and of total body carbon dioxide production were not performed. (3) Studies in experimental models suggest that unbuffered respiratory acidosis may reduce ventilator-induced lung injury.<sup>26</sup> It is therefore possible that physiologic, morphological, and inflammatory variables would have improved as much or more if we reduced V<sub>T</sub> and P<sub>PLAT</sub> without carbon dioxide removal. (4) None of the patients who had  $28 \leq P_{PLAT} \leq 30$  cm H<sub>2</sub>O during "ARDSNet" ventilation were able to

reach the target P<sub>PLAT</sub> values (25–28 cm H<sub>2</sub>O) with the increase in respiratory rate and bicarbonate infusion. This may be because V<sub>T</sub> in three patients was reduced more than required; P<sub>PLAT</sub> in these patients before initiating extracorporeal carbon dioxide removal was 24.2, 23.3, and 24.1 cm H<sub>2</sub>O, values that are lower than the target P<sub>PLAT</sub>. Moreover tris-hydroxymethyl aminomethane, a non-carbon dioxide-generating buffer that was recently shown to efficiently manage respiratory acidosis,<sup>27,28</sup> was not used in the current study.

Gattinoni *et al.* hypothesized that, "to rest the lung," oxygenation *via* mechanical ventilation could be dissociated from decarboxylation *via* extracorporeal carbon dioxide removal.<sup>5</sup> In that study, mechanical ventilation was limited to apneic oxygenation and to 3–5 sighs every minute with peak inspiratory pressure not higher than 35–45 cm H<sub>2</sub>O; PEEP ranged between 15 and 25 cm H<sub>2</sub>O. Carbon dioxide removal was performed by using a pump-driven veno-venous bypass, allowing blood flow to pass through two membrane lungs (9 m<sup>2</sup> total membrane surface area). Extracorporeal blood flow was progressively raised from 200 to 300 ml/min to the selected maintenance flow (20–30% of cardiac output). Although the observed mortality rate was lower than expected, several episodes of severe bleeding were reported.<sup>5</sup> A subsequent randomized clinical trial did not confirm these data.<sup>6</sup> Concerns have been raised regarding the



standard use of extracorporeal support<sup>6,29</sup> because of the high incidence of serious complications such as hemorrhage, hemolysis, and neurologic impairments.<sup>8</sup> As a result, extracorporeal carbon dioxide removal has been restricted to the sickest patients in whom all other treatments have failed<sup>30</sup> and to centers with large expertise.<sup>31</sup>

Retrospective evaluation of the *ARDSnet* database suggested that  $V_T$  reduction would have improved outcome, even in patients who already had  $P_{PLAT} < 30$  cm H<sub>2</sub>O.<sup>4</sup> Moreover, physiologic<sup>32</sup> and morphological<sup>3</sup> evidences of tidal hyperinflation have been described in patients in whom the *ARDSnet* strategy resulted in  $28 \leq P_{PLAT} \leq 30$  cm H<sub>2</sub>O. These data have therefore challenged the view of extracorporeal support only as rescue therapy<sup>33,34,35</sup> and have generated the hypothesis that extracorporeal carbon dioxide removal may be incorporated in a lung protective strategy to allow further reduction of  $V_T$  and  $P_{PLAT}$ .<sup>9</sup>

The concept originally developed by Pesenti *et al.* of removing "only a portion of carbon dioxide production"<sup>10</sup> has been recently implemented in new devices that may reduce side effects, complexity, and costs of extracorporeal carbon dioxide removal.<sup>19,33</sup> Bein *et al.* recently reported the use of a pump-less extracorporeal device in ARDS patients.<sup>34</sup> Retrospective analysis of 90 patients demonstrated that using this device was possible to obtain physiologic values of  $P_{aCO_2}$  (31–42 mmHg) and pH (7.38–7.50) despite ventilation with low  $V_T$  (320–470 ml). However, the authors reported a complication rate of 24%, including limb ischemia, compartment syndrome, and intracranial hemorrhage. In addition, continuous intravenous infusion of norepinephrine was needed to maintain the pressure gradient between arterial and venous blood.

In the current study, carbon dioxide removal was performed through a dedicated pump-driven extracorporeal veno-venous circuit with a neonatal membrane lung and a hemofilter coupled in series (fig. 2). The main elements that characterize and differentiate this system are: (1) a blood flow lower than the one used in standard carbon dioxide removal (191–422 ml/min [5–10% of cardiac output] *versus* 1.5–2.0 l/min [20–30% of cardiac output])<sup>5,6,36</sup>; (2) a small neonatal membrane lung (0.33 m<sup>2</sup>) instead of two large adult membrane lung (3–4.5 m<sup>2</sup> each)<sup>5,6,36</sup>; (3) the use of 14-French double-lumen catheters instead of large 21- to 28-French double- or single-lumen catheters<sup>9</sup>; (4) a priming volume smaller than currently used (140–160 ml *vs.* 1,500–1,800 ml)<sup>37</sup>; (5) a relatively small infusion rate of heparin (3–19 IU/kg) and less hypocoagulation than used in previous studies (activated partial thromboplastin time ratio of 1.1–1.7 *vs.* 2.0–2.5).<sup>5,6</sup>

Seventy-two hours of use of this extracorporeal bypass was associated to a  $33.6 \pm 6.3\%$  reduction of  $P_{aCO_2}$  (from  $73.6 \pm 11.1$  to  $48.5 \pm 6.3$  mmHg,  $P < 0.001$ ) sufficient to normalize arterial pH (from  $7.20 \pm 0.02$  to  $7.38 \pm 0.04$ ,  $P < 0.001$ ) while ventilating patients with  $V_T$

ranging between 167 and 340 ml (3.7–4.6 ml/Kg PBW) and minute ventilation ranging between 8.1 and 11.9 l/min. No adverse events in terms of vein perforation, significant bleeding, hemodynamic instability, ischemic/gangrenous bowel, pneumothorax, and renal, infectious, metabolic, thromboembolic, and neurologic complications were observed during the  $141 \pm 69$  h in which the device was in clinical use. However, the level of blood flow required to normalize arterial pH (up to 422 ml/h) was relatively high for a circuit like the one used in the current study<sup>38</sup>; therefore, the 14-French double-lumen catheter had to be replaced in three cases by two 8-French simple-lumen catheters (one for each femoral vein).

Reabsorption atelectasis may occur during mechanical ventilation with low  $V_T$ , depending on the  $F_{IO_2}$ , the regional ventilation/perfusion ratios and the end-expiratory lung volume.<sup>17</sup> In a recent study, Dembinsky *et al.* randomized animals with ARDS to be ventilated for 24 h with a  $V_T$  of 3 ml/kg or with a  $V_T$  of 6 ml/kg, consequent respiratory acidosis was managed in the former group removing carbon dioxide *via* a pumpless system.<sup>18</sup> The study showed that, despite a significant reduction of  $P_{PLAT}$ , organ function and organ injury assessment did not reveal significant improvements when compared with conventional strategy. On the contrary, pulmonary gas exchange was impaired because of increased pulmonary ventilation/perfusion mismatch. In the current study, after 72 h of Lower *ARDSnet*/Carbon Dioxide Removal strategy, we observed (1) the reduction of lung weight and of the extent of the nonaerated and poorly aerated; (2) the increase of the extent of the normally aerated CT lung compartments lung (table 2); (3) a significant improvement of  $P_{aO_2}/F_{IO_2}$  (from  $136 \pm 30$  to  $221 \pm 56$ ;  $P < 0.001$ ) (fig. 5). These differences may be explained by the fact that, whereas PEEP was set to 5 cm H<sub>2</sub>O in both groups in the Dembinsky *et al.* study, PEEP in our study was increased from  $12.1 \pm 2.5$  cm H<sub>2</sub>O to  $15.2 \pm 0.8$  cm H<sub>2</sub>O ( $P < 0.001$ ).<sup>12,39</sup>

In conclusion, this study suggests that further reduction of  $V_T$  minimizes tidal hyperinflation and attenuates pulmonary inflammation in ARDS patients who have a  $P_{PLAT}$  ranging between 28 and 30 cm H<sub>2</sub>O when ventilated with the *ARDSnet* ventilation. Extracorporeal carbon dioxide removal effectively and safely managed the respiratory acidosis consequent to  $V_T$  lower than 6 l/kg PBW and reestablished a normal arterial pH. This proof of concept study provides preliminary clinical evidence that extracorporeal lung support may integrate conventional care and allow the use of more protective ventilator settings. Additional clinical studies are required to further confirm these results.

## References

1. Malhotra A: Low-tidal-volume ventilation in the acute respiratory distress syndrome. *N Engl J Med* 2007; 357:1113–20

2. ARDS Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000; 342:1301-8
3. Terragni PP, Rosboch G, Tealdi A, Corneo E, Menaldo E, Davini O, Gandini G, Herrmann P, Mascia L, Quintel M, Slutsky AS, Gattinoni L, Ranieri VM: Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2007; 175:160-6
4. Hager DN, Krishnan JA, Hayden DL, Brower RG: Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. *Am J Respir Crit Care Med* 2005; 172:1241-5
5. Gattinoni L, Pesenti A, Mascheroni D, Marcolin R, Fumagalli R, Rossi F, Iapichino G, Romagnoli G, Uziel L, Agostoni A, Kolobow T, Damia G: Low-frequency positive-pressure ventilation with extracorporeal CO<sub>2</sub> removal in severe acute respiratory failure. *JAMA* 1986; 256:881-6
6. Morris AH, Wallace CJ, Menlove RL, Clemmer TP, Orme JF Jr, Weaver LK, Dean NC, Thomas F, East TD, Pace NL, Suchyta MR, Beck E, Bombino M, Siting DF, Bohm S, Hoffmann B, Becks H, Butler S, Pearl J, Rasmussen B: Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO<sub>2</sub> removal for adult respiratory distress syndrome. *Am J Respir Crit Care Med* 1994; 149:295-305
7. Deslauriers J, Awad JA: Is extracorporeal CO<sub>2</sub> removal an option in the treatment of adult respiratory distress syndrome? *Ann Thorac Surg* 1997; 63:1581-2
8. Conrad SA, Rycus PT, Dalton H: Extracorporeal Life Support Registry Report 2004. *ASAIO J* 2005; 51:4-10
9. Mielck F, Quintel M: Extracorporeal membrane oxygenation. *Curr Opin Crit Care* 2005; 11:87-93
10. Pesenti A, Rossi GP, Pelosi P, Brazzi L, Gattinoni L: Percutaneous extracorporeal CO<sub>2</sub> removal in a patient with bullous emphysema with recurrent bilateral pneumothoraces and respiratory failure. *Anesthesiology* 1990; 72:571-3
11. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994; 149:818-24
12. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, Schoenfeld D, Thompson BT: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med* 2004; 351:327-36
13. Gattinoni L, Caironi P, Cressoni M, Chiumello D, Ranieri VM, Quintel M, Russo S, Patroniti N, Cornejo R, Bugedo G: Lung recruitment in patients with the acute respiratory distress syndrome. *N Engl J Med* 2006; 354:1775-86
14. Ramsay MA, Savege TM, Simpson BR, Goodwin R: Controlled sedation with alpha<sub>2</sub>-agonists. *BMJ* 1974; 2:656-9
15. Decalot F, Maggioro SM, Jonson B, Duvaldestin P, Brochard L: Pressure-volume curves with and without muscle paralysis in acute respiratory distress syndrome. *Intensive Care Med* 2006; 32:1322-8
16. Conti GVV, Rocco M, DeBlasi RA, Lappa A, Bufi M, Antonelli M, Gasparetto A: Paralysis has no effect on chest wall and respiratory system mechanics of mechanically ventilated, sedated patients. *Intensive Care Med* 1995; 21:808-12
17. Grasso S, Mascia L, Del Turco M, Malacarne P, Giunta F, Brochard L, Slutsky AS, Ranieri VM: Effects of recruiting maneuvers in patients with acute respiratory distress syndrome ventilated with protective ventilatory strategy. *Anesthesiology* 2002; 96:795-802
18. Dembinski R, Hochhausen N, Terbeck S, Uhlig S, Dassow C, Schneider M, Schachtrupp A, Henzler D, Rossaint R, Kuhlen R: Pumpless extracorporeal lung assist for protective mechanical ventilation in experimental lung injury. *Crit Care Med* 2007; 35:2359-66
19. Livigni S, Maio M, Ferretti E, Longobardo A, Potenza R, Rivalta L, Selvaggi P, Vergano M, Bertolini G: Efficacy and safety of a low-flow veno-venous carbon dioxide removal device: Results of an experimental study in adult sheep. *Crit Care* 2006; 10:R151
20. Lynch JE, Riley JB: Microemboli detection on extracorporeal bypass circuits. *Perfusion* 2008; 23:23-32
21. Shuhann RI, Singer M, Rock J: Continuous renal replacement therapy: Keeping the circuit open: Lessons from the lab. *Blood Purif* 2002; 20:275-81
22. Jones NL: An obsession with CO<sub>2</sub>. *Appl Physiol Nutr Metab* 2008; 33:641-50
23. Le Gall S Jr, Saulnier P: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. *JAMA* 1993; 270:2957-63
24. Grasso S, Terragni P, Mascia L, Fanelli V, Quintel M, Herrmann P, Hedenslierna G, Slutsky AS, Ranieri VM: Airway pressure-time curve profile (stress index) detects tidal recruitment/hyperinflation in experimental acute lung injury. *Crit Care Med* 2004; 32:1018-27
25. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, Bruno F, Slutsky AS: Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: A randomized controlled trial. *JAMA* 1999; 282:54-61
26. Laffey JG, O'Carrollin D, McLoughlin P, Kavanagh BP: Permissive hypercapnia-role in protective lung ventilatory strategies. *Intensive Care Med* 2004; 30:347-56
27. Kallet RH, Jasmer RM, Luce JM, Lin LH, Marks JD: The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM). *Am J Respir Crit Care Med* 2000; 161:1149-53
28. Weber T, Tschernich H, Sitzwohl C, Ullrich R, Germann P, Zimpfer M, Shaden RN, Huemer G: Tromethamine buffer modifies the depressant effect of permissive hypercapnia on myocardial contractility in patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2000; 162:1361-5
29. Morris AH: Extracorporeal support and patient outcome: Credible causality remains elusive. *Crit Care Med* 2006; 34:1551-2
30. Lewandowski K, Rossaint R, Pappert D, Gerlach H, Slama KJ, Weldemariam H, Frey DJ, Hoffmann O, Keske U, Falke KJ: High survival rate in 122 ARDS patients managed according to a clinical algorithm including extracorporeal membrane oxygenation. *Intensive Care Med* 1997; 23:819-35
31. Bartlett RH, Roloff DW, Custer JR, Younger JG, Hirschi RB: Extracorporeal life support: The University of Michigan experience. *JAMA* 2000; 283:904-8
32. Grasso S, Stripoli T, De Michele M, Bruno F, Moschetta M, Angelelli G, Munno I, Ruggiero V, Anacleto R, Cafarelli A, Driessen B, Fiore T: ARDSnet ventilatory protocol and alveolar hyperinflation: Role of positive end-expiratory pressure. *Am J Respir Crit Care Med* 2007; 176:761-7
33. Reng M, Philipp A, Kaiser M, Pfeifer M, Gruene S, Schoelmerich J: Pumpless extracorporeal lung assist and adult respiratory distress syndrome. *Lancet* 2000; 356:219-20
34. Bein T, Weber F, Philipp A, Prasser C, Pfeifer M, Schmid FX, Butz R, Birnbaum D, Taeger K, Schlitt HJ: A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia. *Crit Care Med* 2006; 34:1372-7
35. Gattinoni L, Caironi P, Carlesso E: How to ventilate patients with acute lung injury and acute respiratory distress syndrome. *Curr Opin Crit Care* 2005; 11:69-76
36. Pesenti A, Pelizzola A, Mascheroni D, Uziel L, Pirovano E, Fox U, Gattinoni L, Kolobow T: Low frequency positive pressure ventilation with extracorporeal CO<sub>2</sub> removal (LEPPV-ECCO<sub>2</sub>R) in acute respiratory failure (ARF): Technique. *Trans Am Soc Artif Intern Organs* 1981; 27:263-6
37. Gattinoni L, Mascheroni D, Torresin A, Marcolin R, Fumagalli R, Vesconi S, Rossi GP, Rossi F, Baglioni S, Bassi F, Nistri G, Pesenti A: Morphological response to positive end expiratory pressure in acute respiratory failure. Computerized tomography study. *Intensive Care Med* 1986; 12:137-42
38. Ronco C: Continuous renal replacement therapies in the treatment of acute renal failure in intensive care patients. Part 2. Clinical indications and prescription. *Nephrol Dial Transplant* 1994; 9(Suppl 4):201-9
39. Corbridge TC, Wood LD, Crawford GP, Chudoba MJ, Yanos J, Sznajder JI: Adverse effects of large tidal volume and low PEEP in canine acid aspiration. *Am Rev Respir Dis* 1990; 142:311-5